12 insiders have filed at GMED since 2023Q3: names, roles, reported stakes, and each person's buying and selling record from SEC Form 3/4/5 filings.
| name | role | reported stake | % of company | buys (3y) | sells (3y) |
|---|---|---|---|---|---|
| Davidar David D | Director | 676.1k | 0.489% | 9 sells $12.4M | |
| Paul David C | Executive Chairman | 60.4k | 0.044% | ||
| Wolterman Dan | Director | 24.0k | 0.017% | ||
| Deford John A | Director | 15.6k | 0.011% | ||
| Rhoads Ann D | Director | 15.4k | 0.011% | 5 sells $3.0M | |
| Norwalk Leslie V | Director | 10.4k | <0.01% | 4 sells $1.2M | |
| Huller Kelly | EVP, Gc, Corporate Secretary | 9 sells $5.0M | |||
| Lemaitre Dan | Director | 3 sells $5.3M | |||
| Scavilla Daniel T | President, CEO | 2 sells $15.9M | |||
| Pfeil Keith W | COO, CFO | 2 sells $1.3M | |||
| Kline Kyle | Senior Vice President, CFO | 2 sells $2.0M | |||
| Zarrilli Stephen T | Director | 1 sells $2.1M |
Full register at boothcheck.com/insiders/GMED. Stakes are the newest reported Form 3/4/5 balances (they update only when insiders file). Sales counted include pre-scheduled plan sales, labeled. A filed record, not a forecast. Nothing here is investment advice.